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Abstract
Objectives—Available D-dimer assays have low specificity and may increase radiographic
testing for pulmonary embolism (PE). To help clinicians better target testing, this study sought to
quantify the effect of risk factors for a positive quantitative D-dimer in patients evaluated for PE.
Methods—This was a prospective, multicenter, observational study. Emergency department
(ED) patients evaluated for PE with a quantitative D-dimer were eligible for inclusion. The main
outcome of interest was a positive D-dimer. Odds ratio (ORs) and 95% confidence intervals (CIs)
were determined by multivariable logistic regression. Adjusted estimates of relative risk were also
calculated.
Results—A total of 4,346 patients had D-dimer testing, of whom 2,930 (67%) were women. A
total of 2,500 (57%) were white, 1,474 (34%) were black or African American, 238 (6%) were
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Hispanic, and 144 (3%) were of other race or ethnicity. The mean (±SD) age was 48 (±17) years.
Overall, 1,903 (44%) D-dimers were positive. Model fit was adequate (c-statistic = 0.739, Hosmer
and Lemeshow p-value = 0.13). Significant positive predictors of D-dimer positive included
female sex; increasing age; black (vs. white) race; cocaine use; general, limb, or neurologic
immobility; hemoptysis; hemodialysis; active malignancy; rheumatoid arthritis; lupus; sickle cell
disease; prior venous thromboembolism (VTE; not under treatment); pregnancy and postpartum
state; and abdominal, chest, orthopedic, or other surgery. Warfarin use was protective. In contrast,
several variables known to be associated with PE were not associated with positive D-dimer
results: body mass index (BMI), estrogen use, family history of PE, (inactive) malignancy,
thrombophilia, trauma within 4 weeks, travel, and prior VTE (under treatment).
Conclusions—Many factors are associated with a positive D-dimer test. The effect of these
factors on the usefulness of the test should be considered prior to ordering a D-dimer.
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Plasma D-dimer measurement is commonly used as the first test in patients suspected of
having acute pulmonary embolism (PE). D-dimer testing is noninvasive and rapid, so it is
not surprising that the availability of these tests can increase the number of patients
evaluated for possible PE.1 However, low specificity limits the usefulness of D-dimer
testing. Specificity is typically between 40% and 60%, leading to a high rate of false-
positive results.2
Several factors, other than PE or deep vein thrombosis (DVT), are associated with positive
D-dimer results. Some, such as advanced age, malignancy, and pregnancy, have been
described in the medical literature.3–9 However, most prior studies have evaluated D-dimer
testing in a select population of patients with a particular risk factor, rather than in an
undifferentiated population of patients evaluated for PE.10–12 As a result, the ability to
adjust results for the large variety of conditions that may elevate the D-dimer has been
limited. In addition, risk factors have generally been studied as broad categories (e.g., recent
surgery, history of cancer), but whether the described effects are consistent across more
detailed subcategories (e.g., type of surgery, active vs. inactive malignancy) is not well
known. We used data obtained from a large multicenter study of emergency department
(ED) patients evaluated for PE to identify factors associated with a positive D-dimer result
and quantify the effect of each factor in a multivariable analysis.
Methods
Study Design
This was a prospective, multicenter, observational study of ED patients undergoing testing
for possible PE. The institutional review board of each participating institution approved the
protocol.
Study Setting and Population
Data were collected from May 1, 2003, to March 31, 2007. This study analyzed data from
10 academic medical centers and two community hospitals in the United States.
Patients were eligible for enrollment if the treating clinician ordered a D-dimer to rule out
PE. All D-dimer tests were ordered as part of an evaluation for acute PE, and studies ordered
to evaluate DVT without PE, or other diagnoses, did not trigger enrollment.
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Study Protocol
Details of study enrollment are described elsewhere.10 After a diagnostic test for PE was
ordered, but before results were known, we prospectively collected data describing patient
demographics, presenting signs and symptoms, and comorbid illnesses. A study investigator
uploaded data into a Web-based, secure, electronic data collection form.13 The Web-based
data collection instrument was programmed with logic that did not permit missing or
nonsense data.
Potential predictors were collected prospectively at the time of the PE evaluation. Predictor
variables described a variety of conditions, including demographics, past medical history
and comorbidities, and medications (Table 1). Surgery and trauma were considered positive
if they occurred in the past 4 weeks and if the trauma was significant enough to require
hospitalization. Travel was defined as any travel lasting greater than 6 hours, occurring
within the past 4 weeks.
The outcome of interest was a positive D-dimer result. The decision to order a D-dimer was
at the discretion of the evaluating physician. D-dimer assays were those used for routine
clinical care at participating institutions. We analyzed patients from participating institutions
where a quantitative D-dimer assay was available, including Advanced (Dade Behring,
Marburg, Germany), Biopool Minutex (diaPharma, West Chester, OH), Hemosil (Dade
Behring), Liatest (Diagnostica Stago, Asnières sur Seine, France), MDA (bioMérieux SA,
Marcy-l'Etoile, France, formerly Organon Teknika Corporation, Durham, NC), or VIDAS
(bioMérieux SA). Tests were performed as a part of routine clinical care by personnel
working in each hospital's laboratory, blinded to the goals of the study. The positive and
negative cutoff for each assay was defined by the institution where the test was used and
was generally consistent with manufacturers' recommendations. Liatest, VIDAS, and MDA
D-dimers were considered positive at concentrations of ≥500 ng/mL, Biopool Minutex at
≥250 ng/mL, Hemosil at ≥244 ng/mL, and the Advanced D-dimer at ≥1.6 μg/mL.
Data Analysis
The purpose of our study was to provide guidance to physicians prior to ordering a D-dimer,
so we included both true positive (positive D-dimer results in patients diagnosed with PE)
and false positive (positive D-dimer results in patients not diagnosed with PE) in our
analysis. We also performed a sensitivity analysis excluding patients diagnosed with PE
(i.e., only including false-positive D-dimers).
We used SAS v 9.l (SAS Institute, Cary, NC) for all of our statistical calculations. Baseline
characteristics are reported as simple proportions, means, and medians. In our primary
analysis we calculated odds ratios (ORs) and 95% confidence intervals (95% CIs) using a
multi-variable logistic regression model, which in addition to potential predictors of positive
D-dimers, also included the D-dimer assay used. To adjust for the high frequency of our
outcome, and better estimate the risk ratio (RR), we then transformed the OR using the
method described by Zhang and Yu.14 Predictor variables were included in the model first
as general predictor categories (e.g., recent surgery). In the event that a predictor was found
to be significantly associated with positive D-dimer results, data describing subcategories of
the predictor (e.g., different types of surgery) were available, and if there were greater than
20 subjects in each subcategory, those subcategories of the predictor were included in the
model. If a general category was found not to be associated with positive D-dimer results,
subcategories of the predictor were not analyzed, but the predictor was kept in the model as
a potential confounder. Age and body mass index (BMI) were considered categorical
variables. However, a separate analysis was performed with these variables considered
ordinal in the model. White race, age <30 years, and BMI <25 were reference groups. For
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subcategories of diseases (e.g., active and inactive malignancy), lack of the disease (e.g., no
cancer) was the reference group. Significant predictors were defined as those where the 95%
CI did not cross unity. Table 1 lists the predictors included in the final multivariable model.
Results
In the original study, 7,940 patients were prospectively enrolled and 6,175 patients were
enrolled in an institution where a quantitative D-dimer was available. Of these patients,
4,356 (71%) had a quantitative D-dimer performed and were therefore included in the
current analysis (Figure 1). The Liatest was the most commonly performed assay (1,466,
34%), followed by the VIDAS (1,262, 29%). A total of 1,003 patients (44%) had a positive
D-dimer. The overall mean age was 47.7(±16.7) years. Among patients with a negative D-
dimer the mean age was 44.2 (±14.1) years, but among those with a positive D-dimer the
mean age was 52.3 (±18.6) years. The majority of patients (2930, 67%) were female. Table
2 describes the baseline characteristics of enrolled patients, stratified by whether D-dimer
was positive or negative.
Results of the multivariable model are presented in Table 3. Model fit was adequate (c-
statistic = 0.739, Hosmer and Lemeshow test p = 0.13). Women were more likely to have a
positive D-dimer than were men. Older age was highly associated with positive D-dimer
(OR = 1.40 [95% CI = 1.32 to 1.47], adjusted RR = 1.19 [95% CI = 1.16 to 1.22] per 10
years after age 30, p < 0.0001). The association with age became statistically significant in
the fourth to fifth decades of life. Patients of African American or black race were more
likely to have a positive D-dimer compared to whites, but there was no observed association
for other races. All categories of surgery were associated with positive D-dimer results.
Active cancer was associated with positive D-dimer results (OR = 2.58 [95% CI = 1.84 to
3.63], adjusted RR = 1.55 [95% CI = 1.36 to 1.72], p < 0.0001), whereas inactive cancer was
not. Immobility was associated with positive D-dimer results, with a 50% to 60% increase
across all categories of immobility, although there was no association with travel. There was
an increasingly positive association between trimester of pregnancy and positive D-dimers.
The association in the first trimester of pregnancy was borderline, but nearly all (96%)
women in the third trimester had a positive D-dimer. In terms of past medical history,
connective tissue disease was associated with a roughly one-third higher risk of a positive
D-dimer and end-stage renal disease with a 45% higher risk, but the strongest disease
association was seen with sickle cell disease/trait (OR = 24.17 [95% CI = 3.08 to 189.53],
adjusted RR = 2.18 [95% CI = 1.62 to 2.28], p = 0.002). Prior venous thromboembolism
(VTE) was associated with a small increase in the odds of D-dimer positivity (OR = 1.41
[95% CI = 1.07 to 1.87], adjusted RR = 1.20 [95% CI = 1.04 to 1.36], p = 0.016), only if the
patient was not actively being treated. The only factor with a significant “ protective effect”
was warfarin use; anti-platelet drugs had no such effect. Overall, variables not associated
with positive D-dimer included antiplatelet drugs, anxiety, asthma, BMI, coronary artery
disease (CAD), congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD), diabetes, estrogen use, family history of PE, hypertension, (inactive) malignancy,
stroke, thrombophilia, trauma within 4 weeks, travel, or VTE (under treatment).
Sensitivity Analysis
When we restricted our multivariable analysis to the 4,122 patients not diagnosed with PE
(i.e., false-positive D-dimers), results were similar (Table 4). The only variables to change
statistical significance were CAD, VTE not under treatment, and smoking, although point
estimates were similar and the lower confidence bounds for these variables were close to
unity in both analyses. Estimated ORs were also similar when we reran our model only
including significant predictors.
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Discussion
To our knowledge, this is the largest and most detailed study yet performed quantifying the
association between clinical factors and positive D-dimer results. We found several factors
to be highly associated with positive D-dimer results. This study has several advantages over
previous studies; with our large sample size, we were able to adjust for a large number of
covariates. This provides a more accurate estimate of the risk of a positive D-dimer, even for
factors previously known to be associated with positive results. In addition, we were able to
identify several factors not previously known to be associated with positive D-dimer results
and describe the association of subcategories of malignancy, surgery, connective tissue
disease, lung disease, and pregnancy—describing the relationship between these factors and
D-dimer results in more detail than was previously available.
We found several findings of particular interest. We confirmed strong associations with age,
surgery, and malignancy, previously described. We also found associations with immobility
and sickle cell disease that were not well known. The adjusted relative risks for these
associations are generally between 1.5 and 2. While this may seem low, it is important to
consider that the baseline risk of a positive D-dimer was 44% in our study, so increasing the
risk by 50% to 100% represents a significant change. We believe that identifying factors
associated with positive D-dimer results, and understanding the strength of the associations,
will help clinicians target their use of D-dimer testing to those patients where the result is
likely to be the most useful. These results may also aid the development of decision
instruments that guide the use of D-dimer testing and the evaluation of patients suspected of
having PE.
Our data support the association between older age and positive D-dimer results that has
been described previously.8,9 There does not seem to be a great effect below the age of 50
years, with patients younger than 50 years having a negative D-dimer approximately 60% of
the time. In contrast, there is a drop to 42% in patients 60–69 years old, to 31% in patients
70–79 years old, and only 17% in patients older than 80 years. Clinicians should consider
the low likelihood of a negative D-dimer before ordering the test in patients more than 60
years old.
We also found that recent surgery increases the odds of a positive D-dimer by approximately
60%. More than two-thirds of our patients who had undergone recent surgery had a positive
D-dimer. While elevated D-dimer values after surgery are understandable, most previous
reports have studied enrolled patients at the time of surgery, showing that postoperative
patients have a high rate of D-dimer positivity.10–12 Our study is the most detailed
exploration to date of the association between recent surgery and D-dimer results in patients
being evaluated for PE. By studying an undifferentiated population of patients, and
comparing those who had recent surgery to those who had not, we were also able to
determine the relative effect of surgery on the odds of a positive D-dimer result.
We also studied the relationship between malignancy and D-dimer results. Previous authors
have shown that patients with cancer were much more likely to have a positive D-dimer,
with a number needed to rule out equal to 8.6.6 However, our study has the advantage of
being able to distinguish between active and inactive malignancy. Our results show a strong
association for patients with malignancy that is actively being treated or palliated. However,
we found no association in patients whose cancer is inactive or has been completely treated.
Clinicians should distinguish between active and inactive cancer when assessing the
likelihood of a positive D-dimer.
The association we found for immobility seems to vary little depending on the type of
immobility. This is in contrast to a recent study from our database demonstrating that the
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risk of PE is different depending on the type of immobility.15 In our study, regardless of
whether a patient's immobility was described as generalized, limb, or neurologic, the risk of
a positive D-dimer increased by 50% to 60%. While immobility is known to be related to PE
risk,15 to the authors' knowledge, this is the first study to demonstrate an independent
association between immobility and D-dimer positivity. Two prior studies investigated the
issue of hypercoagulability during a simulated airplane flight in 10 healthy subjects and one
subject who was heterozygous for factor V Leiden and found no association.16,17 These
results are consistent with our finding of no association between recent travel and D-dimer
results. However, our definition of immobility included patients with prolonged or
permanent immobility and complete or near complete inability to mobilize one or more
limbs. This likely explains the significant association we found. We believe that the
pathophysiology of hypercoagulability associated with immobility should be investigated
further.
Our data support a strong association between sickle cell disease/trait and D-dimer
positivity, such that D-dimer testing is likely to be of limited utility in ruling out PE in these
patients. Prior studies have demonstrated elevated D-dimer levels in sickle cell patients,
particularly during vaso-occlusive crises.18,19 While we did not distinguish between patients
having a painful crisis, it is reasonable to conclude that the high frequency of D-dimer
positivity may be related to concomitant vaso-occlusive crises in patients with sickle cell
disease. Clinicians should be aware of this possibility and treat their patients accordingly.
Finally, it is worth noting that many of the above conditions (e.g., age, immobility,
malignancy, pregnancy) both increase the risk of PE and elevate the D-dimer. This is
demonstrated in our data as well. We found that factors known to increase the risk of PE,
such as immobility (except neurologic), active malignancy, thrombophilia, a history of VTE,
and recent surgery (except chest surgery) all had ratios of false to true D-dimer results that
were lower than that of the study population as a whole. For ordinal factors, such as
increasing age and BMI, the ratio decreased linearly. Increasing physician estimate of
pretest probability of PE was also inversely proportional to the ratio of false to true D-dimer
results. These findings are consistent with known associations between these factors and the
risk of PE and with our prior research.20 Conversely, certain inflammatory conditions
without well-established associations with the risk of PE (rheumatoid arthritis, sickle cell
disease, asthma) had high ratios of false to true D-dimer results. D-dimer use in patients with
these conditions is likely to yield a large number of false positives for each subject ruled out
for PE. Interestingly, we found that some of the above conditions known to increase the risk
of PE were not associated with increased D-dimer values. We found no association between
BMI or smoking and D-dimer positivity, although large epidemiologic studies have
demonstrated their association with PE.20–24 Similarly, we found no association between
known thrombophilia or family history of VTE and positive D-dimers. Thus, even in the
presence of strong family history or known thrombophilia, D-dimer testing may be useful.
We found no association with recent trauma, although trauma is a heterogeneous disease,
and we did not attempt to quantify the amount of bleeding or clotting that might have
occurred in each patient. Last, we found a relatively weak association between prior VTE
and positive D-dimers, but only in patients who were not being actively treated.
Limitations
This was a large multicenter study with an observational design. The selection of patients
appropriate for D-dimer testing was left to the discretion of the treating physician, which
may have biased the results. It is possible that, because patients with conditions (e.g.,
malignancy) known to elevate the D-dimer may not have been selected for testing, we have
underestimated the association of these factors. However, many of the factors we describe,
Kabrhel et al. Page 6
Acad Emerg Med. Author manuscript; available in PMC 2013 January 05.
$watermark-text
$watermark-text
$watermark-text
including subcategories of known associations, were not previously so well known that they
would likely have altered physician test ordering. Nonetheless, our results probably should
not be compared to studies that purported to follow a rigid study protocol. We enrolled
patients in academic and community centers, resulting in a heterogeneous population with a
variety of D-dimer assays used. We adjusted our analysis for the D-dimer assay used, to
account for differences in test characteristics across assays, but we did not specifically
explore differences between assays. We included patients diagnosed with PE in our primary
analysis. We did so to provide guidance to clinicians trying to determine whether a D-dimer
is likely to be positive and therefore less useful in ruling out PE. It is likely that a
homogenous population of patients with true-positive D-dimers would be different than one
with false-positive D-dimers. However, we found no major differences in our associations
when we performed a sensitivity analysis excluding PE-positive patients. Finally, our
analysis was meant to be exploratory and was designed to identify as many predictors of
positive D-dimers as possible. We did not seek to create the most efficient model, but rather
to include a broad array of potential confounders. However, when we excluded
nonsignificant predictors from our model, results were similar.
Conclusions
Many factors are associated with a positive D-dimer test. Age, surgery, immobility, and
pregnancy are all strongly associated with D-dimer positivity. Active malignancy is
associated, but inactive malignancy is not. Several factors that are known to be associated
with pulmonary embolism are not associated with a positive D-dimer. Clinicians should
consider these associations when they weigh the usefulness of D-dimer testing for patients
with suspected pulmonary embolism.
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Figure 1.
Study enrollment. PE = pulmonary embolism.
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Table 1
Predictors Included in Final Multivariable Model
Predictor Categories
Age (yr)* <30, 30–39, 40–49, 50–59, 60–69, 70–79, ≥80
Antiplatelet drug use† Yes/no
Anxiety Yes/no
BMI <25.0, 25.0–29.9, 30.0–34.9, ≥35.0
CAD Yes/no
Cerebrovascular disease‡ Yes/no
CHF Yes/no
Cocaine use Yes/no
Connective tissue disease Systemic lupus erythematosis, rheumatoid arthritis, other
Diabetes mellitus Yes/no
D-dimer assay Advanced, Biopool, Hemosil, Liatest, MDA, Vidas
Estrogen replacement therapy Yes/no
Family history of VTE Yes/no
Sex Female, male
Hemodialysis Yes/no
Hemoptysis Yes/no
Hypertension Yes/no
Lung disease Asthma, COPD, other
Malignancy Active, inactive
Pregnancy First trimester, second trimester, third trimester, ≤4 weeks postpartum
Sickle cell disease or trait Yes/no
Smoking Yes/no
Thrombophilia Yes/no
Immobility Generalized, limb, neurologic
Race Asian, Black or African American, Hispanic, white, other
Surgery Abdominal, chest, orthopedic, other
Trauma Yes/no
Travel Yes/no
Warfarin use Yes/no
VTE history None, under treatment, not under treatment
BMI = body mass index; CAD = coronary artery disease (a history of angina, myocardial infarction, or coronary artery revascularization
procedure); CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; VTE = venous thromboembolism (deep vein
thrombosis or PE).
*Age was considered categorical, although a separate analysis was also performed where age was included in the model as an ordinal variable.
†Antiplatelet drugs include aspirin, ticlopidine, and clopidogrel.
‡Cerebrovascular disease includes any history of stroke or transient ischemic attack.
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Table 2
Characteristics of Enrolled Patients
Characteristic Total, n (%) D-dimer Negative, n (%) D-dimer Positive, n (%) Ratio of False- to True-
positive D-dimers
Enrolled 4,356 (100) 2,453 (56) 1,903 (44) 7.8
Female 2,930 (67) 1,320 (45) 1,610 (55) 9.5
Age (yr)
 <30 605 (14) 373 (62) 232 (38) 14.5
 30–39 961 (22) 642 (67) 319 (33) 8.4
 40–49 954 (22) 619 (65) 335 (35) 8.6
 50–59 798 (18) 468 (59) 330 (41) 6.3
 60–69 507 (12) 217 (43) 290 (57) 8.1
 70–79 328 (8) 100 (30) 228 (70) 6.4
 ≥80 203 (5) 34 (17) 169 (83) 5.8
Race/ethnicity
 Black or African American 1,474 (34) 753 (51) 721 (49) 8.2
 Hispanic 238 (5) 155 (65) 83 (35) 40.5
 White 2,500 (57) 1,454 (58) 1,046 (42) 6.9
 Other 144 (3) 91 (63) 53 (37) 9.6
Pretest probability of PE*
 Low (<15%) 3,224 (74) 1,206 (37) 2,018 (63) 14.1
 Intermediate (15%–40%) 933 (21) 561 (60) 372 (40) 5.6
 High (>40%) 191 (4) 132 (69) 59 (31) 1.5
BMI
 <25 1,517 (35) 871 (57) 646 (43) 9.4
 25–29.9 1,240 (28) 695 (56) 545 (44) 7.5
 30–34.9 790 (18) 447 (57) 343 (43) 7.4
 ≥35 809 (19) 440 (54) 369 (46) 6.4
Cocaine use 68 (2) 31 (46) 37 (54) 17.5
Family history of PE 538 (12) 331 (62) 207 (38) 4.9
Immobility
 General 243 (6) 71 (29) 172 (71) 4.9
 Limb 73 (2) 21 (29) 52 (71) 3.3
 Neurologic 26 (1) 8 (31) 18 (69) 8.0
Hemoptysis 116 (3) 45 (39) 71 (61) 10.8
Medication use
 Antiplatelet 652 (15) 290 (44) 362 (56) 6.9
 Estrogen 400 (9) 249 (62) 151 (38) 5.3
 Warfarin 178 (4) 84 (47) 94 (53) 5.7
Past medical history
 Anxiety 548 (13) 335 (61) 213 (39) 10.2
 CAD 416 (10) 152 (37) 264 (63) 10.5
 Cerebrovascular disease 151 (3) 67 (44) 84 (56) 15.8
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Characteristic Total, n (%) D-dimer Negative, n (%) D-dimer Positive, n (%) Ratio of False- to True-
positive D-dimers
 CHF 287 (7) 99 (34) 188 (66) 8.0
 Connective tissue disease
  Rheumatoid arthritis 76 (2) 30 (39) 46 (61) 22.0
  Systemic lupus erythematosis 53 (1) 22 (42) 31 (58) 9.3
  Other connective tissue disease 26 (1) 11 (42) 15 (58) 4.0
 Diabetes 556 (13) 243 (44) 313 (56) 9.4
 Hemodialysis 38 (1) 12 (32) 26 (68) 25
 Hypertension 1,503 (35) 696 (46) 807 (54) 7.9
 Lung disease
  Asthma 478 (11) 292 (61) 186 (39) 15.9
  COPD 273 (6) 107 (39) 166 (61) 10.1
 Malignancy
  Active 203 (5) 59 (29) 144 (71) 4.5
  Inactive 211 (5) 95 (45) 116 (55) 7.3
 Sickle cell disease or trait 15 (0) 1 (7) 14 (93) 13.0
 Thrombophilia 45 (1) 24 (53) 21 (47) 4.3
 VTE
  Under treatment 118 (3) 56 (47) 62 (53) 2.9
  Not under treatment 258 (6) 118 (46) 140 (54) 4.6
Pregnancy
 First trimester 18 (0) 8 (44) 10 (56)
—
†
 Second trimester 31 (1) 7 (23) 24 (77) —
 Third trimester 23 (1) 1 (4) 22 (96) —
 Postpartum 65 (1) 19 (29) — —
Smoking 1,635 (38) 905 (55) 730 (45) 11.0
Surgery
 Abdominal 72 (2) 18 (25) 54 (75) 5.8
 Chest 34 (1) 10 (29) 24 (71) 11.0
 Orthopedic 49 (1) 15 (31) 34 (69) 2.8
 Other 37 (1) 11 (30) 26 (70) —
Trauma 36 (1) 17 (47) 19 (53) 8.5
Travel 398 (9) 261 (66) 137 (34) 6.2
BMI = body mass index; CAD = coronary artery disease (a history of angina, myocardial infarction, or coronary artery revascularization
procedure); CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; PE = pulmonary embolism; VTE = venous
thromboembolism (deep vein thrombosis or PE).
*
Pretest probability determined by treating physician.
†No patients who had D-dimer performed were diagnosed with PE.
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